Author:
Sakurai Satomi,Matsui Kazuhiro,Narukawa Mamoru
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference23 articles.
1. Hirano M, Yamada M, Tanaka T, et al. Surveys/research exploring Japanese phase I studies in global drug development: are they necessary prior to joining global clinical trials? Clin Pharmacol Drug Dev. 2021;10(12):1410–8. https://doi.org/10.1002/cpdd.1044.
2. Zhao Q, Brett M, Van Osselaer N, et al. Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects. J Clin Pharmacol. 2002;42(9):1002–10.
3. Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016;127(13):1633–41. https://doi.org/10.1182/blood-2015-06-650226.
4. Johansson S, Rosenbaum DP, Knutsson M, Leonsson-Zachrisson M. A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers. Clin Exp Nephrol. 2017;21(3):407–16. https://doi.org/10.1007/s10157-016-1302-8.
5. US Food and Drug Administration. Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials; draft guidance for industry 2022. https://www.fda.gov/media/157635/download. Accessed 29 Sep 2023.